Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Cancer Chemistry

Abstract 2457: Mechanisms of membrane binding of K-Ras4B farnesylated hypervariable region

Hyunbum Jang, Sherwin J. Abraham, Tanmay S. Chavan, Ben Hitchinson, Lyuba Khavrutskii, Nadya I. Tarasova, Ruth Nussinov and Vadim Gaponenko
Hyunbum Jang
1National Cancer Institute at Frederick, Frederick, MD;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sherwin J. Abraham
2Stanford University, Stanford, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanmay S. Chavan
2Stanford University, Stanford, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ben Hitchinson
3University of Illinois at Chicago, Chicago, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lyuba Khavrutskii
1National Cancer Institute at Frederick, Frederick, MD;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nadya I. Tarasova
1National Cancer Institute at Frederick, Frederick, MD;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruth Nussinov
1National Cancer Institute at Frederick, Frederick, MD;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vadim Gaponenko
3University of Illinois at Chicago, Chicago, IL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-2457 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

K-Ras4B belongs to a family of small GTPases that regulates cell growth, differentiation and survival. Kras is frequently mutated in cancer. K-Ras4B modulates downstream signaling at different lipid microdomains. K-Ras4B association with the plasma membrane through its farnesylated and positively charged C-terminal hypervariable region (HVR) is critical to its oncogenic function. HVR farnesylation plays an important role in Ras signaling, but the structural mechanisms and consequences of farnesyl-induced membrane binding are poorly understood and the basis for Ras localization to certain parts of plasma membrane is unknown. Application of confocal microscopy, surface plasmon resonance, and molecular dynamics (MD) simulations revealed that K-Ras4B is distributed between rigid lipid rafts and disordered non-raft regions of the plasma membrane. Its membrane binding domain interaction with phospholipids is driven by membrane fluidity. The farnesyl group spontaneously inserts into the disordered lipid microdomains containing unsaturated phospholipids, while the rigid microdomains composed of tightly packed saturated lipids restrict the farnesyl group penetration. We speculate that the resulting farnesyl protrusion towards the cell interior allows oligomerization of K-Ras4B membrane binding domain in rigid microdomains. Unlike other Ras isoforms, K-Ras4B HVR contains a single farnesyl modification and positively charged polylysine sequence. The high positive charge not only modulates specific HVR binding to anionic phospholipids, but the farnesyl's membrane orientation. Phosphorylation of Ser181 prohibits spontaneous farnesyl membrane insertion. We speculate that if the farnesyl group is not inserted into the membrane, it may serve in cooperative binding of other K-Ras4B molecules, thus leading to dimerization. In this case, the protein binds the membrane using electrostatic interaction between its positively charged HVR and the negatively charged membrane phospholipids. In the case of disordered phospholipid domains, the farnesyl group burial in the phospholipids tends to hinder its interactions. The mechanism illuminates the roles of HVR modifications in K-Ras4B targeting to microdomains of the plasma membrane and suggests an additional function for HVR in regulation of Ras signaling. Elucidating the mechanism for K-Ras4B localization at different membrane microdomains is important for in-depth understanding of Ras-effector interactions mediating signaling pathways. Funded by Frederick National Laboratory for Cancer Research, National Institutes of Health, under contract HHSN261200800001E.

Citation Format: Hyunbum Jang, Sherwin J. Abraham, Tanmay S. Chavan, Ben Hitchinson, Lyuba Khavrutskii, Nadya I. Tarasova, Ruth Nussinov, Vadim Gaponenko. Mechanisms of membrane binding of K-Ras4B farnesylated hypervariable region. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2457. doi:10.1158/1538-7445.AM2015-2457

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 2457: Mechanisms of membrane binding of K-Ras4B farnesylated hypervariable region
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract 2457: Mechanisms of membrane binding of K-Ras4B farnesylated hypervariable region
Hyunbum Jang, Sherwin J. Abraham, Tanmay S. Chavan, Ben Hitchinson, Lyuba Khavrutskii, Nadya I. Tarasova, Ruth Nussinov and Vadim Gaponenko
Cancer Res August 1 2015 (75) (15 Supplement) 2457; DOI: 10.1158/1538-7445.AM2015-2457

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 2457: Mechanisms of membrane binding of K-Ras4B farnesylated hypervariable region
Hyunbum Jang, Sherwin J. Abraham, Tanmay S. Chavan, Ben Hitchinson, Lyuba Khavrutskii, Nadya I. Tarasova, Ruth Nussinov and Vadim Gaponenko
Cancer Res August 1 2015 (75) (15 Supplement) 2457; DOI: 10.1158/1538-7445.AM2015-2457
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Cancer Chemistry

  • Abstract 6550: WD105, a novel decursin derivative, showed greater growth inhibition and androgen receptor suppression in LNCaP human prostate cancer cells
  • Abstract 5689: CH7233163, a mutant-selective EGFR inhibitor, overcomes osimertinib resistant EGFR-T790M/C797S
  • Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models
Show more Cancer Chemistry

Poster Presentations - Proffered Abstracts

  • Abstract 6550: WD105, a novel decursin derivative, showed greater growth inhibition and androgen receptor suppression in LNCaP human prostate cancer cells
  • Abstract 5689: CH7233163, a mutant-selective EGFR inhibitor, overcomes osimertinib resistant EGFR-T790M/C797S
  • Abstract 5691: SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate cancer (CRPC) models
Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Chemical Biology and Structure-Function Studies of Cancer Mechanisms

  • Abstract 2456: The transmembrane domain of prostate specific membrane antigen: Deciphering the role of the Small-XXX-Small motif in oligomerization
  • Abstract 2447: Development of Hsp90 paralog specific inhibitors with mitochondrial drug delivery system
Show more Poster Presentations - Chemical Biology and Structure-Function Studies of Cancer Mechanisms
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement